Compositions monovalent for CD28 binding and methods of use
Murray McKinnon, Doylestown, PA (US); Steven G. Nadler, Princeton, NJ (US); Suzanne J. Suchard, Portland, OR (US); Brendan Classon, Princeton, NJ (US); Steve Holmes, Cambridge (GB); Olga Ignatovich, Cambridge (GB); Christopher Plummer, Romsey (GB); and Steve Grant, Swaffham Prior (GB)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US); and Domantis Limited, Brentford (GB)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US); and Domantis Limited, Middlesex (GB)
Filed on Nov. 2, 2020, as Appl. No. 17/086,565.
Application 17/086,565 is a division of application No. 15/870,121, filed on Jan. 12, 2018, granted, now 10,919,965.
Application 13/415,914 is a division of application No. 12/505,166, filed on Jul. 17, 2009, granted, now 8,168,759, issued on May 1, 2012.
Application 15/870,121 is a continuation of application No. 14/740,709, filed on Jun. 16, 2015, granted, now 9,908,937, issued on Mar. 6, 2018.
Application 14/740,709 is a continuation of application No. 13/415,914, filed on Mar. 9, 2012, granted, now 9,085,629, issued on Jul. 21, 2015.
Claims priority of provisional application 61/162,121, filed on Mar. 20, 2009.
Claims priority of provisional application 61/082,078, filed on Jul. 18, 2008.
Prior Publication US 2021/0047414 A1, Feb. 18, 2021
1. A domain antibody (dAb) comprising an amino acid sequence that differs from that of SEQ ID NO:59, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, or SEQ ID NO: 86 by no more than 10 amino acids, wherein the dAb binds to CD28.